CAS 871700-17-3
:Trametinib
Description:
Trametinib is a selective inhibitor of mitogen-activated protein kinase (MEK) 1 and MEK2, which are key components of the MAPK signaling pathway involved in cell proliferation and survival. It is primarily used in the treatment of certain types of melanoma and other cancers characterized by mutations in the BRAF gene. Trametinib is classified as an antineoplastic agent and is often administered in combination with BRAF inhibitors to enhance therapeutic efficacy. The substance is typically presented as a pale yellow to off-white solid and is soluble in organic solvents such as dimethyl sulfoxide (DMSO) and ethanol, but has limited solubility in water. Its mechanism of action involves the inhibition of downstream signaling pathways that promote tumor growth, thereby leading to reduced cell proliferation and increased apoptosis in cancer cells. Trametinib is administered orally and is subject to specific dosing regimens based on the patient's condition and response to treatment. As with many targeted therapies, it may have associated side effects, including skin rash, diarrhea, and potential cardiovascular effects.
Formula:C26H23FIN5O4
InChI:InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)
InChI key:InChIKey=LIRYPHYGHXZJBZ-UHFFFAOYSA-N
SMILES:N(C1=C2C(N(C(=O)N(C2=O)C3CC3)C4=CC(NC(C)=O)=CC=C4)=C(C)C(=O)N1C)C5=C(F)C=C(I)C=C5
Synonyms:- Acetamide, N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]-
- G 02442104
- Gsk 212
- Gsk-1120212
- Jtp 74057
- Mekinist
- N-[3-[3-Cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide
- Trametinib
- N-[3-[3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]acetamide
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 10 products.
Trametinib-d4
CAS:Formula:C26H19D4FIN5O4Color and Shape:White To Off-White SolidMolecular weight:619.43Trametinib-13C-d3
CAS:Formula:C2513CH20D3FIN5O4Color and Shape:White To Off-White SolidMolecular weight:619.41Trametinib
CAS:<p>Trametinib</p>Formula:C26H23FIN5O4Purity:≥98%Color and Shape: solidMolecular weight:615.39g/molTrametinib
CAS:<p>Trametinib (GSK1120212), an ATP-noncompetitive MEK 1/2 inhibitor (IC50: 0.7/0.9 nM), weakly inhibits >180 kinases.</p>Formula:C26H23FIN5O4Purity:98% - 99.96%Color and Shape:SolidMolecular weight:615.39Trametinib-13C6
CAS:Controlled Product<p>Applications Trametinib-13C6 is the labelled compound form of Trametinib (C988930), which is used in the systematic treatment of advanced cutaneous melanoma. An EGFR kinase inhibitor and potent MEK inhibitor.<br>References Ercan, D., et al.: Canc. Disc., 2, 934 (2012); Mackiewicz-Wysocka, M., et al.: Exp. Opin. Investig. Drugs., 22, 181 (2013);<br></p>Formula:C6C20H23FIN5O4Color and Shape:NeatMolecular weight:621.351Trametinib
CAS:Controlled Product<p>Applications Used in the systematic treatment of advanced cutaneous melanoma. An EGFR kinase inhibitor and potent MEK inhibitor.<br>References Ercan, D. et al.: Canc. Disc., 2, 934 (2012); Mackiewicz-Wysocka, M. et al.: Exp. Opin. Investig. Drugs., 22, 181 (2013);<br></p>Formula:C26H23FIN5O4Color and Shape:Off-WhiteMolecular weight:615.39Trametinib
CAS:<p>Inhibitor of MEK kinase; anti-neoplastic</p>Formula:C26H23O4N5FIPurity:Min. 95%Color and Shape:White PowderMolecular weight:615.39 g/mol
